Tags: Drug.
Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid which is being investigated as a treatment of Alzheimer’s disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune which licensed the drug in 2006 to Genentech Inc. Its original name RG7412 refers to its inventor at AC Immune.In May 2012 it was announced that the efficacy of crenezumab will be tested in a five-year trial against early-onset Alzheimer’s disease.